Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

Completed

Conditions studied: Congestive Heart Failure

In brief

The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312.

Key facts

Study ID

NCT00785044

Run by

GE Healthcare

People needed

471

Starts

2008-05-01

Expected to finish

2010-02-01

Last updated by the study team

2017-04-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject was a Heart Failure subject who signed informed consent for MBG311, MBG312, or MBG312C.
• The subject was administered 123I-mIBG in MBG311, MBG312, or MBG312C.
• The subject completed the late planar imaging assessments (at a minimum) required by the protocols for MBG311, MBG312, or MBG312C.
• The subject agreed to allow the investigator access to medical records, including those relating to subject death should this occur.

You may not qualify if…

• The subject withdrew or was withdrawn from MBG311, MBG312, or MBG312C.
• The subject was considered lost-to-follow-up (6 months without contact) in MBG311, MBG312, or MBG312C.

Where it is running

• GE Healthcare — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.